Lantern Pharma Inc. (LTRN)
$0.71-4.05%Close
SELLCRISIS · day 44
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9M
- Beta
- 2.32
- P/E (TTM)
- -0.44
- Short % float
- 5.06%
- Days to cover
- 1.3
- SI change
- -12.9%
- 1W
- -25.26%
- 1M
- -58.48%
- vs SPY 1W
- -25.12%
- vs SPY 1M
- -60.99%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 5
- GROWTH
- 37
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-273.8%
REV YoY-
ROE-456.4%
EPS YoY-
ROA-216.8%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.44
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-2.74
P/FCF-
EV/EBITDA-0.13
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.96
ND/EBITDA-
BETA2.32
Company news
FAQ
- What is LOPJLB’s current signal on LTRN?
- LOPJLB’s latest quantitative signal on Lantern Pharma Inc. (LTRN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LTRN in?
- Lantern Pharma Inc. (LTRN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Lantern Pharma Inc. (LTRN) do?
- Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also adv…